Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
NCT ID: NCT05951179
Last Updated: 2026-01-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
131 participants
INTERVENTIONAL
2023-09-15
2030-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this Phase 2 study (TARA-002-101-Ph2) is to further assess the safety and efficacy of TARA-002 at the RP2D which has been established in the Phase 1a dose finding study (TARA-002-101-Ph1a).
This Phase 2 study includes participants with CIS NMIBC (± Ta/T1) with active disease, defined as disease present at last tumor evaluation (within 3 months) prior to signing the ICF.
Participants will be enrolled into one of 2 cohorts:
Cohort A:
* Participants with CIS (± Ta/T1) who are BCG naive, or
* Participants with CIS (± Ta/T1) who are BCG exposed and have not received intravesical BCG for at least 24 months prior to the most recent CIS diagnosis
Cohort B:
* Participants who are BCG unresponsive
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)
NCT05085990
Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)
NCT05085977
A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy
NCT03404791
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
NCT04919512
A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States
NCT07309445
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TARA-002
TARA-002 is a lyophilized biological preparation for instillation containing cells of Streptococcus pyogenes (Group A, type 3) Su strain.
TARA-002
All participants will receive 6 weekly instillations of TARA-002 at the established RP2D (First Treatment Period). Participants who are eligible for reinduction after the First Treatment Period will receive 6 additional weekly doses of TARA-002 instillation as part of the Second Treatment Period. Participants confirmed to have a complete response after the First Treatment Period will receive 3 additional weekly doses of TARA-002 instillation as maintenance during the Second Treatment Period. All eligible participants will receive 3 weekly doses of TARA-002 instillation as part of the Third Treatment Period (maintenance) at Months 6, 9, 12, 15, and 18. Following the Third Treatment Period, all participants will continue to the Follow up Period from Month 21 until Month 60.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TARA-002
All participants will receive 6 weekly instillations of TARA-002 at the established RP2D (First Treatment Period). Participants who are eligible for reinduction after the First Treatment Period will receive 6 additional weekly doses of TARA-002 instillation as part of the Second Treatment Period. Participants confirmed to have a complete response after the First Treatment Period will receive 3 additional weekly doses of TARA-002 instillation as maintenance during the Second Treatment Period. All eligible participants will receive 3 weekly doses of TARA-002 instillation as part of the Third Treatment Period (maintenance) at Months 6, 9, 12, 15, and 18. Following the Third Treatment Period, all participants will continue to the Follow up Period from Month 21 until Month 60.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants who have voluntarily given written informed consent after the nature of the study has been explained according to applicable requirements prior to study entry
* Central histologic confirmation of high-grade non-muscle invasive CIS (± Ta/T1) with active disease
* Participants who are BCG naive, or participants who are BCG exposed and have not received intravesical BCG for at least 24 months prior to the most recent CIS diagnosis (Cohort A). Participants with CIS (± Ta/T1) who are BCG unresponsive.
Exclusion Criteria
* Central confirmed variant histology
* Concomitant prostatic or upper tract urothelial involvement per Investigator's assessment
* Nodal and metastatic disease are excluded if they existed at any time (whether present or in the past)
* Any history of ≥ T2 bladder cancer that existed at any point in time in the participant's history
For more information on eligibility criteria, please contact the Sponsor
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Protara Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chief Scientific Operations Officer
Role: STUDY_DIRECTOR
Protara Therapeutics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Urology Centers of Alabama
Homewood, Alabama, United States
Mayo Clinic
Phoenix, Arizona, United States
East Valley Urology Center of Arizona
Queen Creek, Arizona, United States
Arkansas Urology
Little Rock, Arkansas, United States
Michael Oefelein Clinical Trials
Bakersfield, California, United States
Urology Group of Southern California
Los Angeles, California, United States
University of California Irvine Medical Center
Orange, California, United States
Genesis Research
San Diego, California, United States
Genesis Research LLC
Torrance, California, United States
Colorado University - Anshutz
Aurora, Colorado, United States
AdventHealth Medical Group Urology of Denver
Denver, Colorado, United States
Advanced Urology
Lakewood, Colorado, United States
Urology Associates of Denver
Lone Tree, Colorado, United States
University of Florida Health Jacksonville
Gainesville, Florida, United States
Mayo Clinic
Jacksonville, Florida, United States
Comprehensive Urologic Care
Lake Barrington, Illinois, United States
Southern Urology
Lafayette, Louisiana, United States
Ochsner Health LSU - Regional Urology
Shreveport, Louisiana, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
Mayo Clinic
Rochester, Minnesota, United States
Washington University
St Louis, Missouri, United States
Specialty Clinic Research of St. Louis
St Louis, Missouri, United States
AccuMed Research Associates
Garden City, New York, United States
University of Rochester, Department of Urology
Rochester, New York, United States
Montefiore Medical Center
The Bronx, New York, United States
University of Toledo
Toledo, Ohio, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Carolina Urologic Research Center
Myrtle Beach, South Carolina, United States
Conrad Person Clinic
Memphis, Tennessee, United States
Urology Associates PC
Nashville, Tennessee, United States
Amarillo Urology Research
Amarillo, Texas, United States
Urology Partners of North Texas
Arlington, Texas, United States
Urology Austin, LLC
Austin, Texas, United States
Houston Metro Urology
Houston, Texas, United States
Houston Methodist Hospital
Houston, Texas, United States
Clinical Trial Network
Houston, Texas, United States
UT Health San Antonio
San Antonio, Texas, United States
Virginia Urology
Richmond, Virginia, United States
Centro Argentino de Urologia
CABA, , Argentina
Hospital Sirio Libanes
CABA, , Argentina
Centro Urologico Profesor Bengio SA
Córdoba, , Argentina
CEMAIC
Córdoba, , Argentina
Clinica Privada Independencia
Munro, , Argentina
Fuji City General Hospital
Nova Lima, Minas Gerais, Brazil
Kyushu University Hospital
Nova Lima, Minas Gerais, Brazil
Office of Lucas Nougeria MA
Nova Lima, Minas Gerais, Brazil
Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Nucleo de Pesquisa Clinica do Rio Grande so Sul
Porto Alegre, Rio Grande do Sul, Brazil
Centro de Urologia Avancada
Porto Alegre, Rio Grande do Sul, Brazil
Komaki City Hospital
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Clinicas da UNICAMP
Campinas, São Paulo, Brazil
Instituto Dor de Pesquisa e Ensino
Jardim Paulista, São Paulo, Brazil
Faculdade de Medicina ABC-CEPHO
Santo André, São Paulo, Brazil
Exdeo Clinical Research Inc
Abbotsford, British Columbia, Canada
Jonathan Giddes Medicine Professional Corporation
Brampton, Ontario, Canada
Sunnybrook Research Institute
Toronto, Ontario, Canada
UHN Princess Margaret Cancer Centre Princess Margaret Hospital
Toronto, Ontario, Canada
Niigata Cancer Center Hospital
Niigata, Niigata, Japan
Japanese Red Cross Osaka Hospital
Osaka, Osaka, Japan
Tokyo University Medical Center Sakura Hospital
Fuji-shi, Shizuoka, Japan
Arensia Kapitanivka - PPDS
Kapitanivka, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Use Central Contact
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TARA-002-101-Ph2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.